Top

Published in:

01-06-2016 | Original Article

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction

Authors: Wei-Ren Chen, Xue-Qin Shen, Ying Zhang, Yun-Dai Chen, Shun-Ying Hu, Geng Qian, Jing Wang, Jun-Jie Yang, Zhi-Feng Wang, Feng Tian

Published in: Endocrine | Issue 3/2016

Abstract

The influence of glucagon-like peptide-1 has been studied in several studies in patients with acute myocardial infarction, but not in patients with non-ST-segment elevation myocardial infarction (NSTEMI). We planned to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI. A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days. Eighty-three patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function. At 3 months, the primary endpoint, the difference in the change in left ventricular ejection fraction between the two groups was +4.7 % (liraglutide vs. placebo 95 % CI +0.7 to +9.2 % P = 0.009) under intention-to-treat analysis. The difference in decrease in serum glycosylated hemoglobin levels was −0.2 % (liraglutide vs. placebo 95 % CI −0.1 to −0.3 %; P < 0.001). Inflammation and oxidative stress improved significantly in the liraglutide group compared to the placebo group. Liraglutide could improve left ventricular function in patients with NSTEMI, making it a potential adjuvant therapy for NSTEMI.

G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, J.F. Tanguay, J.M. ten Berg, D.L. Miller, T.M. Costigan, J. Goedicke, J. Silvain, P. Angioli, J. Legutko, M. Niethammer, Z. Motovska, J.A. Jakubowski, G. Cayla, L.O. Visconti, E. Vicaut, P. Widimsky, Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med. 369(11), 999–1010 (2013)CrossRefPubMed

D. Aronson, H. Hammerman, M.R. Kapeliovich, A. Suleiman, Y. Agmon, R. Beyar, W. Markiewicz, M. Suleiman, Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care 30(4), 960–966 (2007)CrossRefPubMed

J. Lønborg, N. Vejlstrup, H. Kelbæk, H.E. Bøtker, W.Y. Kim, A.B. Mathiasen, E. Jørgensen, S. Helqvist, K. Saunamäki, P. Clemmensen, L. Holmvang, L. Thuesen, L.R. Krusell, J.S. Jensen, L. Køber, M. Treiman, J.J. Holst, T. Engstrøm, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33(12), 1491–1499 (2012)CrossRefPubMed

A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, G. Pujadas, K. Esposito, D. Giugliano, S. Genovese, Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36(8), 2346–2350 (2013)CrossRefPubMedPubMedCentral

L.A. Nikolaidis, A. Doverspike, T. Hentosz, L. Zourelias, Y.T. Shen, D. Elahi, R.P. Shannon, Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther. 312(1), 303–308 (2005)CrossRefPubMed

L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C. Stolarski, Y.T. Shen, R.P. Shannon, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8), 955–961 (2004)CrossRefPubMed

M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009)CrossRefPubMedPubMedCentral

L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, D. Elahi, R.P. Shannon, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8), 962–965 (2004)CrossRefPubMed

K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White, Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur. Heart J. 33(20), 2551–2567 (2012)CrossRefPubMed

10.

Workgroup on Hypoglycemia, American Diabetes Association, Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28(5), 1245–1249 (2005)CrossRef

11.

A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, H.I. Feldman, J.W. Kusek, P. Eggers, Lente F. Van, T. Greene, J. Coresh, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 150(9), 604–612 (2009)CrossRefPubMedPubMedCentral

12.

P.J. Best, D.N. Reddan, P.B. Berger, L.A. Szczech, P.A. McCullough, R.M. Califf, Cardiovascular disease and chronic kidney disease: insights and an update. Am. Heart J. 148(2), 230–242 (2004)CrossRefPubMed

13.

W.L. Miller, R.S. Wright, J.P. Grill, S.L. Kopecky, Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin. Cardiol. 23(10), 751–758 (2000)CrossRefPubMed

14.

M. Parks, C. Rosebraugh, Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N. Engl. J. Med. 362(9), 774–777 (2010)CrossRefPubMed

15.

A. Ganau, R.B. Devereux, M.J. Roman, G. de Simone, T.G. Pickering, P.S. Saba, P. Vargiu, I. Simongini, J.H. Laragh, Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 19(7), 1550–1558 (1992)CrossRefPubMed

16.

G.A. Oswald, S. Corcoran, J.S. Yudkin, Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1(8389), 1264–1267 (1984)CrossRefPubMed

17.

R. Marfella, M. Siniscalchi, K. Esposito, A. Sellitto, U. De Fanis, C. Romano, M. Portoghese, S. Siciliano, F. Nappo, F.C. Sasso, N. Mininni, F. Cacciapuoti, G. Lucivero, R. Giunta, M. Verza, D. Giugliano, Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care 26(11), 3129–3135 (2003)CrossRefPubMed

18.

K. Tanaka, Y. Saisho, T. Kawai, M. Tanaka, S. Meguro, J. Irie, T. Imai, T. Shigihara, J. Morimoto, K. Yajima, Y. Atsumi, I. Takei, H. Itoh, Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr. J. 62(5), 399–409 (2015)CrossRefPubMed

19.

A. Shiraki, J. Oyama, H. Komoda, M. Asaka, A. Komatsu, M. Sakuma, K. Kodama, Y. Sakamoto, N. Kotooka, T. Hirase, K. Node, The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221(2), 375–382 (2012)CrossRefPubMed

20.

B.B. Dokken, L.R. La Bonte, G. Davis-Gorman, M.K. Teachey, N. Seaver, P.F. McDonagh, Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm. Metab. Res. 43(5), 300–305 (2011)CrossRefPubMed

21.

J. Wichmann, M. Ketzel, T. Ellermann, S. Loft, Apparent temperature and acute myocardial infarction hospital admissions in Copenhagen, Denmark: a case-crossover study. Environ. Health 11, 19 (2012)CrossRefPubMedPubMedCentral

22.

R. Ferrari, E. Merli, G. Cicchitelli, D. Mele, A. Fucili, C. Ceconi, Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann. N. Y. Acad. Sci. 1033, 79–91 (2004)CrossRefPubMed

23.

N.B. Perepech, A.O. Nedoshivin, I.V. Nesterova, Neoton and thrombolytic therapy of myocardial infarction. Ter. Arkh. 73(9), 50–55 (2001)PubMed

24.

M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand, M. Zdravkovic, T.D. Le Thi, S. Colagiuri, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight con-trol compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268–278 (2009)CrossRefPubMedPubMedCentral

25.

J. Lønborg, H. Kelbæk, N. Vejlstrup, H.E. Bøtker, W.Y. Kim, L. Holmvang, E. Jørgensen, S. Helqvist, K. Saunamäki, C.J. Terkelsen, M.M. Schoos, L. Køber, P. Clemmensen, M. Treiman, T. Engstrøm, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circulation 5(2), 288–295 (2012)PubMed

26.

J.S. Woo, W. Kim, S.J. Ha, J.B. Kim, S.J. Kim, W.S. Kim, H.J. Seon, K.S. Kim, Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33(9), 2252–2260 (2013)CrossRefPubMed

27.

L.M. McCormick, A.C. Kydd, P.A. Read, L.S. Ring, S.J. Bond, S.P. Hoole, D.P. Dutka, Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circulation 7(2), 274–281 (2014)PubMed

28.

B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, P. Raskin, P.M. Hale, M. Zdravkovic, L. Blonde, LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32(7), 1224–1230 (2009)CrossRefPubMedPubMedCentral

29.

L.E. Robinson, T.A. Holt, K. Rees, H.S. Randeva, J.P. O’Hare, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1), e001986 (2013)CrossRefPubMedPubMedCentral

30.

P.M. Okin, S.E. Kjeldsen, S. Julius, D.A. Hille, B. Dahlöf, J.M. Edelman, R.B. Devereux, All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur. Heart J. 31(18), 2271–2279 (2010)CrossRefPubMed

31.

T. Nozue, M. Yamada, T. Tsunoda, H. Katoh, S. Ito, T. Iwaki, I. Michishita, Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessel. (2015). doi:10.1007/s00380-015-0734-5

32.

A. Undas, I. Wiek, E. Stêpien, K. Zmudka, W. Tracz, Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 31(8), 1590–1595 (2008)CrossRefPubMedPubMedCentral

33.

J.Y. Park, N. Takahara, A. Gabriele, E. Chou, K. Naruse, K. Suzuma, T. Yamauchi, S.W. Ha, M. Meier, C.J. Rhodes, G.L. King, Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49(7), 1239–1248 (2000)CrossRefPubMed

34.

T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.T. Shen, R.P. Shannon, Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317(3), 1106–1113 (2006)CrossRefPubMed

35.

E. Osto, P. Doytcheva, C. Corteville, M. Bueter, C. Dörig, S. Stivala, H. Buhmann, S. Colin, L. Rohrer, R. Hasballa, A. Tailleux, C. Wolfrum, F. Tona, J. Manz, D. Vetter, K. Spliethoff, P.M. Vanhoutte, U. Landmesser, F. Pattou, B. Staels, C.M. Matter, T.A. Lutz, T.F. Lüscher, Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation 131(10), 871–881 (2015)CrossRefPubMed

36.

T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, T. Münzel, Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104(22), 2673–2678 (2001)CrossRefPubMed

Title: Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
Authors: Wei-Ren Chen
Xue-Qin Shen
Ying Zhang
Yun-Dai Chen
Shun-Ying Hu
Geng Qian
Jing Wang
Jun-Jie Yang
Zhi-Feng Wang
Feng Tian
Publication date: 01-06-2016
Publisher: Springer US
Published in: Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-015-0798-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Down-sizing the overzealous search for low-risk thyroid malignancy

Treatment of hypothyroidism: all that glitters is gold?

Pre-training levels of testosterone and sex hormone-binding globulin are not correlated with training adaptations in fat mass and insulin sensitivity in healthy young men

Giant prolactinomas: are they really different from ordinary macroprolactinomas?

Elevated plasma tumor necrosis factor-α receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults

Primary iliopsoas abscess in a patient with diabetic foot

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page